Evidence map›Paper›PMID 41488406›Full record

ArticleInternational journal of particle therapy2026

Outcomes After Fast Neutron Therapy for Locally Advanced Base of Tongue Adenoid Cystic Carcinoma.

Anthony K Heng, August Anderson, Robert D Stewart, George E Laramore, Neil Panjwani, Cristina P Rodriguez, Lauren Shih, Neal Futran, Brittany Barber, Emily Marchiano and 3 more

Abstract read
In one paragraph

Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anthony K HengUniversity of Washington School of Medicine, Seattle, WA, USA.
August AndersonDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Robert D StewartDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
George E LaramoreDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Neil PanjwaniDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Cristina P RodriguezDivision of Hematology & Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Lauren ShihDivision of Hematology & Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Neal FutranDepartment of Otolaryngology Head & Neck Surgery, University of Washington School of Medicine, Seattle, WA, USA.
Brittany BarberDepartment of Otolaryngology Head & Neck Surgery, University of Washington School of Medicine, Seattle, WA, USA.
Emily MarchianoDepartment of Otolaryngology Head & Neck Surgery, University of Washington School of Medicine, Seattle, WA, USA.
Rocco FerrandinoDepartment of Otolaryngology Head & Neck Surgery, University of Washington School of Medicine, Seattle, WA, USA.
Upendra ParvathaneniDepartment of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA.
Jay J LiaoDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Base of tongue (BOT) adenoid cystic carcinoma (ACC) is a rare, locally aggressive malignancy that is typically associated with a high rate of disease recurrence. Surgery alone is rarely curative and highly morbid. Outcomes of systemic therapies and low linear energy transfer radiation therapy (RT) are generally poor. Fast neutron therapy (NRT), a form of high linear energy transfer radiation, is advantageous in treating radioresistant salivary gland malignancies. Long-term cancer control and swallowing outcomes in patients with BOT ACC treated with NRT were retrospectively reviewed. Methods: Between 1994 and 2023, 63 patients ≥18 years (median age 61) with biopsy-confirmed BOT ACC, not treated previously with surgery or RT, underwent 3D-conformal NRT or intensity-modulated neutron therapy (IMNT) for localized M0 (77.8%) or M1 (22.2%) disease. Most patients had (T3-4) primary tumors. Kaplan-Meier method was used to estimate locoregional recurrence-free (LRFS), distant metastasis-free, and overall survival. Late toxicities (≥90 days after NRT) were reported per Common Terminology Criteria for Adverse Events v5.0. Treatment-related and post-treatment percutaneous endoscopic gastrotomy (PEG) tube utilization was evaluated. Results: For the entire cohort, 5-year LRFS was 53.4%, and 5-year overall survival was 75.1%. Among M0 patients, 3-year LRFS was 72.4%, 5-year LRFS was 59.4%, and 5-year distant metastasis-free was 44.1%. Prophylactic PEG tubes were placed in 58.1% of patients; 14.5% remained PEG-dependent ≥90 days post-treatment. Common toxicities included xerostomia and dysphagia. Among evaluable patients, 33.3% required PEG placement after 90 days due to disease or salvage therapy. Neither patient treated with IMNT required long-term PEG use. Conclusions: This is the first study to report clinical outcomes of NRT for BOT ACC. Swallowing outcomes were acceptable, with a low rate of persistent PEG dependence. NRT achieved significant locoregional control in many locally advanced primary tumors. Additional improvements in the therapeutic ratio and functional outcomes may be achievable with IMNT.

Indexed as

Adenoid cystic carcinomaBase of tongueNeutron radiotherapyNeutronsRBE

Identifiers

PMID41488406
PMCPMC12757553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.